{"id":139,"date":"2020-11-30T12:06:38","date_gmt":"2020-11-30T12:06:38","guid":{"rendered":"http:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/?page_id=139"},"modified":"2021-03-19T09:15:40","modified_gmt":"2021-03-19T09:15:40","slug":"innovation-and-technology","status":"publish","type":"page","link":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/innovation-and-technology\/","title":{"rendered":"Innovation and technology"},"content":{"rendered":"

[vc_row full_width=\u00bbstretch_row_content\u00bb el_class=\u00bbprincipio-marcha\u00bb][vc_column css=\u00bb.vc_custom_1588939369209{padding-top: 40px !important;}\u00bb][vc_custom_heading text=\u00bbInnovation and technology\u00bb font_container=\u00bbtag:h2|text_align:center|color:%23ffffff\u00bb use_theme_fonts=\u00bbyes\u00bb css_animation=\u00bbfadeInDownBig\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00bbstretch_row_content\u00bb equal_height=\u00bbyes\u00bb][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1588936329456{padding-top: 5% !important;padding-right: 10% !important;padding-bottom: 5% !important;padding-left: 10% !important;background-color: #f2f2f2 !important;}\u00bb][vc_column_text]<\/p>\n

Emerging lines associated with technology transfer: \u00bb Agustin de Betancourt\u00bb programme<\/h2>\n

The \u201cAgust\u00edn de Betancourt\u201d programme is an initiative of the Council of Tenerife, first established in 2016, to provide support to the research groups and institutes at the ULL, in order to maintain research activity with high potential for technology transfer. It is also committed to the recruitment of human resources with skills for the development of advanced technological products and services that could have an impact on the market, driving their commercial exploitation in priority sectors for the economy of The Canary Islands. After being selected through a public tendering process, the research personnel recruited through this program are brought together with consolidated research groups to carry out their own research projects under the supervision of the group leader.[\/vc_column_text][\/vc_column][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606737952696{background: #e5e5e5 url(http:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-content\/uploads\/sites\/17\/2020\/11\/inves-1.jpg?id=144) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}\u00bb][vc_empty_space height=\u00bb500px\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00bbstretch_row_content\u00bb equal_height=\u00bbyes\u00bb][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606737967474{background: #f2f2f2 url(http:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-content\/uploads\/sites\/17\/2020\/11\/inves-2.jpg?id=141) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}\u00bb][vc_empty_space height=\u00bb500px\u00bb][\/vc_column][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606729073944{padding-top: 5% !important;padding-right: 10% !important;padding-bottom: 5% !important;padding-left: 10% !important;}\u00bb][vc_column_text]<\/p>\n

Active ITB research projects<\/h2>\n

The active ITB research projects that represent emerging lines related to technology transfer are:<\/p>\n

    \n
  1. Identification of new therapeutic targets and the generation of neuroactive peptides in Alzheimer’s disease and other related taupathies<\/strong>\u00a0(\u00abIdentificaci\u00f3n de nuevas dianas terap\u00e9uticas y generaci\u00f3n de p\u00e9ptidos neuroactivos en la enfermedad de Alzheimer y otras taupat\u00edas relacionadas\u00bb. Principal investigator: Carmen Laura Sayas Casanova, PhD; PI-ULL: N\u00e9stor Torres Darias; Department of Biochemistry, Microbiology, Cellular Biology and Genetics, ULL). Programme of \u00abDrug Development & Target Identification\u00bb.<\/li>\n
  2. Proof of concept for a non-invasive technology for the early diagnosis in Sporadic Alzheimer’s Disease based on circulating exosomes<\/strong>\u00a0(\u00abPrueba de concepto para una tecnolog\u00eda no-invasiva de diagn\u00f3stico temprano de Enfermedad de Alzheimer Espor\u00e1dica basada en exosomas circulantes. Principal investigator: Daniel V. Guebel, PhD; PI-ULL: N\u00e9stor Torres Darias; Department of Biochemistry, Microbiology, Cellular Biology and Genetics, ULL). Programme of \u00abDrug Development & Target Identification\u00bb.<\/li>\n
  3. Neuromodulatory techniques as new therapeutic approaches against addictive behaviours<\/strong>\u00a0(\u00abT\u00e9cnicas neuromodulatorias como nuevas aproximaciones terap\u00e9uticas frente a las conductas adictivas\u00bb). Principal investigator: Julien Dampur\u00e9, PhD; PI-ULL: Horacio Barber Friend; Department of Cognitive, Social and Organisational Psychology, ULL). Programme of \u00abNeurobiology & Brain-Related Diseases\u00bb.<\/li>\n
  4. The induction of autophagy through D2R\/D3R receptors in Parkinson\u2019s and Huntington\u2019s disease.<\/strong>\u00a0(\u00abInducci\u00f3n de autofagia a trav\u00e9s de receptores D2R\/D3R en la enfermedad de Parkinson y la de Huntington\u00bb. Principal investigator: Diego Luis-Ravelo, PhD; PI-ULL: Tom\u00e1s Gonz\u00e1lez Hern\u00e1ndez; Department of Basic Medical Sciences, ULL). Programme of \u00abNeurobiology & Brain-Related Diseases\u00bb.<\/li>\n
  5. MetSPLAT: An in vivo platform for preclinical drug trials against metabolic syndrome.\u00a0<\/strong>Agust\u00edn de Betancourt project (Principal investigator: Silvia Vel\u00e1zquez Garc\u00eda, PhD; PI-ULL: Diego \u00c1lvarez de la Rosa; Department of Basic Medical Sciences, ULL). \u00abChronic & Age-Related Diseases\u00bb Programme.<\/li>\n
  6. In vivo screening based on the reversal of cellular phenotypes to find new drugs that inhibit the Chk1 kinase involved in cancer<\/strong>\u00a0(\u201cRastreo in vivo basado en la reversi\u00f3n de fenotipo celular para encontrar nuevos f\u00e1rmacos inhibidores contra la quinasa Chk1 implicada en c\u00e1ncer\u201d. Principal investigator: David Gillespie, PhD; PI-ULL: Eduardo Salido Ruiz; Department of Basic Medical Sciences, ULL). \u00abGenetic & Rare Diseases\u00bb Programme.<\/li>\n
  7. Development and application of nanostructured magnetic platforms in the detection of pathogens: environmental applications in the agri-food industry and in water intended for human consumption<\/strong>\u00a0(\u00abDesarrollo y aplicaci\u00f3n de plataformas magn\u00e9ticas nanoestructuradas en la detecci\u00f3n de agentes pat\u00f3genos: aplicaciones medioambientales, en la industria agroalimentaria y en aguas de consumo humano\u00bb. Principal investigator: \u00cd\u00f1igo Fern\u00e1ndez Bats, PhD; PI-ULL: Jos\u00e9 Luis Gonz\u00e1lez Mora; Department of Basic Medical Sciences, ULL). Programme of \u00abNeurobiology & Brain-Related Diseases\u00bb.<\/li>\n
  8. Gene Editing Service<\/strong>\u00a0(\u00abServicio de edici\u00f3n g\u00e9nica\u00bb. Principal investigator: Belinda Rivero P\u00e9rez, PhD; PI-ULL: Eduardo Salido Ruiz; Department of Basic Medical Sciences). \u00abChronic & Age-Related Diseases\u00bb Programme<\/li>\n
  9. METAPANC<\/strong>: Inhibition of glutamine metabolism as therapy for pancreatic ductal adenocarcinoma (\u00abInhibici\u00f3n del metabolismo de la glutamina como terapia contra el adenocarcinoma ductal pancre\u00e1tico\u00bb. Principal investigator: Miguel X. Fernandes, PhD; PI-ULL: Jos\u00e9 M. Padr\u00f3n; Department ofOrganic Chemistry, ULL). \u00abDrug Development & Target Identification\u00bb Programme.<\/li>\n
  10. MICROFAVAR<\/strong>: Development of a high-resolution, high-speed quantitative phase-contrast microscope for 3D imaging of biological samples (\u00abDesarrollo de un microscopio de contraste de fase cuantitativa de alta resoluci\u00f3n y alta velocidad para la obtenci\u00f3n de im\u00e1genes en 3D de muestras biol\u00f3gicas\u00bb. Principal investigator: Carlos Cair\u00f3s; PI-ULL: \u00c1ngel Acebes, Department of Basic Medical Sciences, ULL). Programme of \u00abNeurobiology & Brain-Related Diseases\u00bb.<\/li>\n<\/ol>\n

    [\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=\u00bbstretch_row_content\u00bb equal_height=\u00bbyes\u00bb][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1588936329456{padding-top: 5% !important;padding-right: 10% !important;padding-bottom: 5% !important;padding-left: 10% !important;background-color: #f2f2f2 !important;}\u00bb][vc_column_text]<\/p>\n

    Technology transfer<\/h2>\n
    \n
      \n
    1. Facility for the Massive Analysis of Genomic Data (Regional Government of Tenerife, CGIEU0000219140). Contract: 2,700,000 \u20ac (2018-2022). Dr Carlos Flores.<\/li>\n
    2. Agreement between the Institute of Technology and Renewable Energies, HUNSC and The Canary Islands Health Research Institute Foundation to contribute to strengthening education, training, research, development and scientific and technological innovation in genomics, precision medicine and biotechnology (OA17\/008). Contract: 320,000 \u20ac (2017-2020). Dr Carlos Flores.<\/li>\n
    3. Collaboration agreement between the The Canary Islands Foundation for Advances in Biomedicine and Biotechnology (Bioavance) and the company Orfan Biotech SL to generate an in vitro model of Huntington’s disease and to validation the proposed approach (\u00abConvenio de colaboraci\u00f3n entre la Fundaci\u00f3n Canaria para el Avance de la Biomedicina y de la Biotecnolog\u00eda (Bioavance) y la empresa Orfan Biotech SL para la realizaci\u00f3n de un modelo in vitro de la enfermedad de Huntington y ensayos de validaci\u00f3n del abordaje propuesto\u00bb). Contract: 15,000 \u20ac (22\/02\/2019 – 01\/10\/2019). Dr Tom\u00e1s Gonz\u00e1lez Hern\u00e1ndez.<\/li>\n
    4. <\/li>\n<\/ol>\n<\/div>\n

      [\/vc_column_text][\/vc_column][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606737980764{background: #e5e5e5 url(http:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-content\/uploads\/sites\/17\/2020\/11\/inves-3.jpg?id=142) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}\u00bb][vc_empty_space height=\u00bb500px\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00bbstretch_row_content\u00bb equal_height=\u00bbyes\u00bb][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606737994504{background: #f2f2f2 url(http:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-content\/uploads\/sites\/17\/2020\/11\/inves-4.jpg?id=143) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}\u00bb][vc_empty_space height=\u00bb500px\u00bb][\/vc_column][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1606729073944{padding-top: 5% !important;padding-right: 10% !important;padding-bottom: 5% !important;padding-left: 10% !important;}\u00bb][vc_column_text]<\/p>\n

      Support and training<\/h2>\n
      \n
        \n
      1. Strategic Plan for Research, Innovation & Management of Intellectual Property Rights (PDF)<\/a><\/li>\n
      2. Resources for Researchers (PDF)<\/a><\/li>\n<\/ol>\n<\/div>\n

        [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

        [vc_row full_width=\u00bbstretch_row_content\u00bb el_class=\u00bbprincipio-marcha\u00bb][vc_column css=\u00bb.vc_custom_1588939369209{padding-top: 40px !important;}\u00bb][vc_custom_heading text=\u00bbInnovation and technology\u00bb font_container=\u00bbtag:h2|text_align:center|color:%23ffffff\u00bb use_theme_fonts=\u00bbyes\u00bb css_animation=\u00bbfadeInDownBig\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00bbstretch_row_content\u00bb equal_height=\u00bbyes\u00bb][vc_column width=\u00bb1\/2″ css=\u00bb.vc_custom_1588936329456{padding-top: 5% !important;padding-right: 10% !important;padding-bottom: 5% !important;padding-left: 10% !important;background-color: #f2f2f2 !important;}\u00bb][vc_column_text] Emerging lines associated with technology transfer: \u00bb Agustin de Betancourt\u00bb programme The \u201cAgust\u00edn de Betancourt\u201d programme is an initiative of the Council of Tenerife, first established in 2016, to…<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-no-title.php","meta":[],"_links":{"self":[{"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/pages\/139"}],"collection":[{"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/comments?post=139"}],"version-history":[{"count":3,"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/pages\/139\/revisions"}],"predecessor-version":[{"id":362,"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/pages\/139\/revisions\/362"}],"wp:attachment":[{"href":"https:\/\/www.ull.es\/institutos\/institute-biomedical-technologies\/wp-json\/wp\/v2\/media?parent=139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}